Robert A Rollins
Overview
Explore the profile of Robert A Rollins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
735
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ding X, Zhu Z, Lapek J, McMillan E, Zhang A, Chung C, et al.
Sci Rep
. 2022 Jul;
12(1):12501.
PMID: 35864202
The synthetic lethal association between BRCA deficiency and poly (ADP-ribose) polymerase (PARP) inhibition supports PARP inhibitor (PARPi) clinical efficacy in BRCA-mutated tumors. PARPis also demonstrate activity in non-BRCA mutated tumors...
2.
Molina-Sanchez P, Ruiz de Galarreta M, Yao M, Lindblad K, Bresnahan E, Bitterman E, et al.
Gastroenterology
. 2020 Aug;
159(6):2203-2220.e14.
PMID: 32814112
Background And Aims: The pattern of genetic alterations in cancer driver genes in patients with hepatocellular carcinoma (HCC) is highly diverse, which partially explains the low efficacy of available therapies....
3.
Qiu J, Sharma S, Rollins R, Paul T
Future Med Chem
. 2020 Jul;
12(15):1415-1430.
PMID: 32723083
Immune dysfunction in the tumor microenvironment occurs through epigenetic changes in both tumor cells and immune cells that alter transcriptional programs driving cell fate and cell function. Oncogenic activation of...
4.
Kung P, Bingham P, Brooun A, Collins M, Deng Y, Dinh D, et al.
J Med Chem
. 2017 Dec;
61(3):650-665.
PMID: 29211475
A new series of lactam-derived EZH2 inhibitors was designed via ligand-based and physicochemical-property-based strategies to address metabolic stability and thermodynamic solubility issues associated with previous lead compound 1. The new...
5.
Kung P, Rui E, Bergqvist S, Bingham P, Braganza J, Collins M, et al.
J Med Chem
. 2016 Dec;
59(24):11196.
PMID: 27936698
No abstract available.
6.
Kung P, Rui E, Bergqvist S, Bingham P, Braganza J, Collins M, et al.
J Med Chem
. 2016 Aug;
59(18):8306-25.
PMID: 27512831
A new enhancer of zeste homolog 2 (EZH2) inhibitor series comprising a substituted phenyl ring joined to a dimethylpyridone moiety via an amide linkage has been designed. A preferential amide...
7.
Barsotti A, Ryskin M, Rollins R
Epigenomics
. 2015 Aug;
7(5):687-90.
PMID: 26317265
No abstract available.
8.
Dann S, Ryskin M, Barsotti A, Golas J, Shi C, Miranda M, et al.
EMBO J
. 2015 May;
34(13):1773-85.
PMID: 25979827
Lat1 (SLC7A5) is an amino acid transporter often required for tumor cell import of essential amino acids (AA) including Methionine (Met). Met is the obligate precursor of S-adenosylmethionine (SAM), the...
9.
ODonnell A, Edwards J, Rollins R, Vander Kraats N, Su T, Hibshoosh H, et al.
J Cancer Ther
. 2015 May;
5(14):1311-1324.
PMID: 25960928
Promoter silencing by ectopic methylation of tumor suppressor genes has been proposed as comparable or equivalent to inactivating mutations as a factor in carcinogenesis. However, this hypotheses had not previously...
10.
Barsotti A, Ryskin M, Zhong W, Zhang W, Giannakou A, Loreth C, et al.
Oncotarget
. 2015 Feb;
6(5):2928-38.
PMID: 25671303
In addition to genetic alterations, cancer cells are characterized by myriad epigenetic changes. EZH2 is a histone methyltransferase that is over-expressed and mutated in cancer. The EZH2 gain-of-function (GOF) mutations...